ATE411017T1 - Verfahren zur beeinflussung neurologischer progression - Google Patents
Verfahren zur beeinflussung neurologischer progressionInfo
- Publication number
- ATE411017T1 ATE411017T1 AT02799240T AT02799240T ATE411017T1 AT E411017 T1 ATE411017 T1 AT E411017T1 AT 02799240 T AT02799240 T AT 02799240T AT 02799240 T AT02799240 T AT 02799240T AT E411017 T1 ATE411017 T1 AT E411017T1
- Authority
- AT
- Austria
- Prior art keywords
- influencing
- neurological progression
- brain
- neurological
- progression
- Prior art date
Links
- 230000000926 neurological effect Effects 0.000 title 1
- 208000003174 Brain Neoplasms Diseases 0.000 abstract 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract 1
- 206010059282 Metastases to central nervous system Diseases 0.000 abstract 1
- 210000004556 brain Anatomy 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000005202 lung cancer Diseases 0.000 abstract 1
- 208000020816 lung neoplasm Diseases 0.000 abstract 1
- 230000007658 neurological function Effects 0.000 abstract 1
- 230000009885 systemic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
- A61K47/546—Porphyrines; Porphyrine with an expanded ring system, e.g. texaphyrine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33965001P | 2001-12-13 | 2001-12-13 | |
| US34658402P | 2002-01-07 | 2002-01-07 | |
| US35309002P | 2002-01-30 | 2002-01-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE411017T1 true ATE411017T1 (de) | 2008-10-15 |
Family
ID=27407352
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02799240T ATE411017T1 (de) | 2001-12-13 | 2002-12-12 | Verfahren zur beeinflussung neurologischer progression |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20030130252A1 (de) |
| EP (1) | EP1465617B1 (de) |
| JP (1) | JP2005511719A (de) |
| KR (1) | KR20040075001A (de) |
| CN (1) | CN1615129A (de) |
| AT (1) | ATE411017T1 (de) |
| AU (1) | AU2002364165B2 (de) |
| CA (1) | CA2469613A1 (de) |
| DE (1) | DE60229437D1 (de) |
| DK (1) | DK1465617T3 (de) |
| ES (1) | ES2315429T3 (de) |
| IL (1) | IL162469A0 (de) |
| MX (1) | MXPA04005715A (de) |
| PL (1) | PL372326A1 (de) |
| PT (1) | PT1465617E (de) |
| WO (1) | WO2003049731A1 (de) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2006206398A1 (en) * | 2005-01-19 | 2006-07-27 | Pharmacyclics, Inc. | A method for treating neurologic diseases |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5252720A (en) * | 1989-03-06 | 1993-10-12 | Board Of Regents, The University Of Texas System | Metal complexes of water soluble texaphyrins |
| US5457183A (en) * | 1989-03-06 | 1995-10-10 | Board Of Regents, The University Of Texas System | Hydroxylated texaphyrins |
| US5776925A (en) * | 1996-01-25 | 1998-07-07 | Pharmacyclics, Inc. | Methods for cancer chemosensitization |
| US6013646A (en) * | 1998-07-02 | 2000-01-11 | Bayer Corporation | Indolocarbazole derivatives useful for the treatment of neurodegenerative diseases and cancer |
-
2002
- 2002-12-12 DE DE60229437T patent/DE60229437D1/de not_active Expired - Fee Related
- 2002-12-12 DK DK02799240T patent/DK1465617T3/da active
- 2002-12-12 PL PL02372326A patent/PL372326A1/xx not_active Application Discontinuation
- 2002-12-12 WO PCT/US2002/039974 patent/WO2003049731A1/en not_active Ceased
- 2002-12-12 AU AU2002364165A patent/AU2002364165B2/en not_active Ceased
- 2002-12-12 EP EP02799240A patent/EP1465617B1/de not_active Expired - Lifetime
- 2002-12-12 JP JP2003550780A patent/JP2005511719A/ja active Pending
- 2002-12-12 PT PT02799240T patent/PT1465617E/pt unknown
- 2002-12-12 MX MXPA04005715A patent/MXPA04005715A/es not_active Application Discontinuation
- 2002-12-12 CN CNA028270924A patent/CN1615129A/zh active Pending
- 2002-12-12 CA CA002469613A patent/CA2469613A1/en not_active Abandoned
- 2002-12-12 ES ES02799240T patent/ES2315429T3/es not_active Expired - Lifetime
- 2002-12-12 KR KR10-2004-7009132A patent/KR20040075001A/ko not_active Ceased
- 2002-12-12 AT AT02799240T patent/ATE411017T1/de not_active IP Right Cessation
- 2002-12-12 IL IL16246902A patent/IL162469A0/xx unknown
- 2002-12-12 US US10/318,659 patent/US20030130252A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1465617A1 (de) | 2004-10-13 |
| US20030130252A1 (en) | 2003-07-10 |
| AU2002364165B2 (en) | 2007-09-20 |
| CA2469613A1 (en) | 2003-06-19 |
| PT1465617E (pt) | 2009-01-23 |
| KR20040075001A (ko) | 2004-08-26 |
| DK1465617T3 (da) | 2009-02-16 |
| ES2315429T3 (es) | 2009-04-01 |
| IL162469A0 (en) | 2005-11-20 |
| CN1615129A (zh) | 2005-05-11 |
| WO2003049731A1 (en) | 2003-06-19 |
| PL372326A1 (en) | 2005-07-11 |
| DE60229437D1 (de) | 2008-11-27 |
| EP1465617B1 (de) | 2008-10-15 |
| AU2002364165A1 (en) | 2003-06-23 |
| MXPA04005715A (es) | 2004-10-15 |
| JP2005511719A (ja) | 2005-04-28 |
| EP1465617A4 (de) | 2005-10-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60225651D1 (de) | Verfahren zur Herstellung ionischer Metallkomplexe | |
| EP1406639A4 (de) | Verfahren zur verbesserung der wirksamkeit von krebstherapien | |
| ZA200305126B (en) | Methods of administering epothilone analogs for the treatment of cancer. | |
| EP1501489A4 (de) | Kombinationstherapie zur behandlung von krebs | |
| TW200508201A (en) | Novel process for the preparation of roflumilast | |
| MY142988A (en) | Novel aminobenzophenone compounds | |
| BR0213424A (pt) | Uso aperfeiçoado de composto antitumoral na terapia contra câncer | |
| ZA200404752B (en) | 6-aminomorphinane derivatives method for the production and use thereof | |
| DE60307710D1 (de) | Verfahren zur Herstellung von Eisenoxiden | |
| DE602004021544D1 (de) | Organische-anorganische Hybrid-Zusammensetzung für" Verfahren | |
| DE60229959D1 (de) | Kombinationstherapie zur behandlung von krebs | |
| DE602005015174D1 (de) | Verfahren zur herstellung von montelukast-natrium | |
| DE502004010131D1 (de) | Pyridopyrimidinone zur behandlung von krebserkrankungen | |
| MXPA04003755A (es) | Endoprotesis vasculares. | |
| AU2003300385A8 (en) | Anticancer compounds | |
| ATE491463T1 (de) | Verfahren zur herstellung von alpha (2) makroglobulin-antigen-molekül-komplexen | |
| DE60229437D1 (de) | Verfahren zur beeinflussung neurologischer progression | |
| IL158184A0 (en) | Anti-muc-1 single chain antibodies for tumor targeting | |
| GB2389532B (en) | The method of treating cancer | |
| DE602004012146D1 (en) | Pyrazolopyrimidine | |
| DE502005000428D1 (de) | Verfahren zur Herstellung von 1,2-Diaminocyclohexan-Platin(II)-Komplexen | |
| HRP20030677A2 (en) | Methods of administering epothilone analogs for the treatment of cancer | |
| DE60214629D1 (de) | Verfahren zur Zersetzung von Michael-Addukten | |
| DE60228444D1 (de) | Verfahren zur herstellung von cumylphenol | |
| TW200600084A (en) | Anti-coronavirus compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1465617 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |